Retatrutide: Clinical trials, mechanism and approval status
Retatrutide: Clinical trials, mechanism and approval status
Evidence-based information about investigational retatrutide, a triple GIP/GLP-1/glucagon receptor agonist.
Overview
Retatrutide is an investigational once-weekly peptide developed by Eli Lilly that activates GIP, GLP-1 and glucagon receptors. Clinical trials have reported substantial average weight reduction, but it is not FDA-approved, trial findings do not establish routine clinical use and long-term benefits and risks remain under study.
Key points
Mechanism
Triple receptor agonism is intended to affect appetite, glucose regulation and energy expenditure.
Evidence
Phase 2 results are promising, while phase 3 trials are needed to define benefits, adverse effects and appropriate use.
Safety
Gastrointestinal effects and heart-rate changes have been reported; complete labeling does not exist because approval has not occurred.
Legal status
FDA states retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition.
How W8MD can help
W8MD can discuss FDA-approved weight-management alternatives and monitor official clinical-trial and regulatory developments. W8MD does not prescribe or sell retatrutide, compounded retatrutide or products labeled “research use only.”
Frequently asked questions
Can I obtain compounded retatrutide?
FDA states retatrutide cannot be used in compounding under federal law.
Is it better than tirzepatide?
Cross-trial comparisons cannot establish superiority, and retatrutide remains investigational.
How can I join a trial?
Search ClinicalTrials.gov and discuss eligibility with the listed research site.
Evidence and authoritative sources
Contact W8MD
W8MD Weight Loss, Sleep & MedSpa provides physician-supervised care in Brooklyn, New York and Northeast Philadelphia. Telehealth may be available for eligible patients based on location and applicable requirements.
Contact W8MD
